CALGARY, Sept. 12, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) is pleased to announce its participation in the following industry conferences in the month of September.
Rodman & Renshaw 18th Annual Global Investment Conference
New York, NY.
September 13th, 2016
Mr. Donald J. McCaffrey, President & Chief Executive Office
BioPharm America 9th Annual International Partnering Conference
September 14th, 2016
Mr. Kenneth Lebioda, Sr. VP Business & Corporate Development
52nd European Association for the Study of Diabetes (EASD) Annual Meeting
September 14th, 2016
Dr. Norman Wong, Chief Scientific Officer
"Apabetalone (RVX-208) acts on epigenetics to lower Major Adverse Cardiovascular Events (MACE) in diabetes patients with atherosclerosis via microbiome activity"
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (RVX.TO).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Last updated on: 13/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.